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Introduction
Since 1980, obesity has doubled worldwide. According 
to the World Health Organization (WHO) report, over 
1.9 billion people aged 18 years and older in 2014 were 
overweight. Of these people, over 600 million were obese 
(1). Obesity is known as a cause of increased development 
of certain chronic diseases. Growing obesity epidemic 
has become a public health crisis worldwide and has 
affected many countries. Besides that, obesity has led to 
numerous socioeconomic and medical consequences in 
these countries (2). 
Materials and Methods
For this mini-review, we used a variety of sources by 
searching through Web of Science, PubMed, EMBASE, 
Scopus and directory of open access journals (DOAJ). 
The search was performed using combinations of the 
following key words and or their equivalents such as; 
Obesity, chronic kidney disease, high blood pressure, 
chronic renal failure, hypertension and diabetes mellitus.
Obesity
Obesity is a complex problem that plays a part in 
many metabolic problems such as diabetes mellitus, 
dyslipidemia, hypertension, and metabolic syndrome. In 
addition, the kidney may be affected by adverse effects of 
obesity. Obesity and overweight were reported to possibly 
have a significant contribution to the pathogenesis of CKD 
in around 14%-30% of the patients (3). Current evidence 
indicates that differences in incidence rate of kidney 
diseases among different regions of the world and also 
different prevalence rates of obesity revealing that obesity 
may be an important risk factor for kidney diseases (4). 
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Chronic kidney disease (CKD) is a health issue that may progress into end-stage renal disease 
(ESRD) and therefore lead to increased mortality from cardiovascular disease. Early detection 
of risk factors for CKD helps to improve them and prevent progression of this disease. Obesity 
is one of the most important yet preventable risk factors for CKD. Obesity is known as a cause 
of increased development of certain chronic diseases and may cause renal damage directly 
through hemodynamic and hormonal factors or indirectly via progression of diabetes and 
hypertension. With increased urban population and income, the diets containing high 
amounts of sugar, fats, and animal products have replaced traditional diets that contain 
highly fibrous complex carbohydrates. Currently, high-calorie foods and sedentary lifestyle 
are associated with obesity among children and adolescents. In 2017, the World’s Kidney Day 
concentrated on obesity as a potent risk factor for development of kidney diseases. 
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Chronic kidney disease and obesity
(CVD) including hypertension and type 2 diabetes and 
decreases high density lipoprotein-cholesterol (5). These 
risk factors are strongly associated with increased risk of 
developing chronic renal failure (CRF) and end-stage renal 
disease (ESRD). Association of obesity with abnormal 
renal function and focal segmental glomerulosclerosis can 
be the primary cause of CKD (3). Obesity may cause renal 
damage directly through hemodynamic and hormonal 
factors or indirectly via progression of diabetes and 
hypertension. Some evidences indicate that obesity and 
diabetes may have similar effects on the kidney (6). Several 
mechanisms have been recommended for association 
of obesity with hypertension, glumerosclerosis, and 
therefore CRF, including changes in internal kidney tissue 
that leads to activation of the renin-angiotensin system, 
renal hyperfiltration, and therefore hypertension and 
glomerulosclerosis(7).
A study determined that abdominal obesity in young 
adults is an independent risk factor for CKD which is 
definitely race-associated. Obese youths are recommended 
to undergo periodical screening for renal function. 
General obesity was demonstrated to be a very important 
determinative risk factor in women, and abdominal 
obesity seems to be associated with renal failure in men 
(8). 
In the past decade, the subjects of World Kidney Day 
that aims to raise awareness of kidney diseases and the 
importance of the kidneys to overall health have been 
specified to different purposes such as protecting the 
kidneys via maintaining normal blood pressure, managing 
diabetes mellitus, protecting heart, CKD, and aging. In 
2017, the World Kidney Day concentrated on obesity as 
a potent risk factor for development of kidney diseases. 
Renal diseases and obesity
CKD is a health issue that may progress into ESRD and 
therefore lead to increased mortality from CVD. Current 
statistics indicate that 10%-16% of adults are suffering 
from CKD in different regions across the world. Several 
predisposing and risk factors have been so far offered 
for development of CKD including genetic factors, age, 
gender, race, culture, family history, medication, smoking, 
socioeconomic status, obesity, and certain comorbidities 
such as hypertension and diabetes (9). Age is an effective 
factor on development of CKD. In people aged over 30 
years, the chance of developing CKD increases by 1.45-
2.18 times per 10-year increase in age. Twenty-three 
percent of dialysis patients have family history of ESRD. 
The families of dialysis patients are recommended to 
undergo screening for kidney diseases (10). In addition, 
according to several studies conducted by different 
approaches, smoking plays role in renal damage through 
increasing microalbuminuria, proteinuria, and serum 
creatinine and decreasing glomerular filtration rates (5). 
Early detection of risk factors for CKD helps to improve 
them and prevent progression of this disease. Obesity is 
one of the most important yet preventable risk factors 
for CKD(11). Pathogenic mechanisms responsible for 
microalbuminuria/proteinuria in obese people displayed 
excessive glomerular filtration rate. Animal and human 
studies demonstrated that obesity led to glomerular 
hyperperfusion and hyperfiltration that in turn cause 
proteinuria and focal segmental glomerulosclerosis (5). 
Besides that, leptin secreted by additional adipose tissue 
can directly lead to renal fibrosis (12). Abnormal hydration 
of fat-free body mass and the patterns of fat distribution 
especially in ESRD can be indicative of association 
between obesity and kidney diseases. In obesity or 
inflammatory conditions such as CKD, ESRD, and heart 
failure, deposition of the subcutaneous adipose tissue is 
diverted toward deposition of perivisceral adipose tissue 
(yellow fat) that, in addition to inducing visceral insulin 
resistance, specifically and significantly develops CD68 
that causes deposition of immune cells in adipose tissue. 
Such immune cells produce further pro-inflammatory 
factors from adipose tissue including leptin, adiponectin, 
resistin, and vasfatin. Adipose tissue is related to other 
organs of the body through biological cytokines secreted 
by the adipose tissue named adiponectin (13,14). 
Nervous tissue helps to regulate and control feeding and 
accumulation of fat in the adipose tissue through the 
messages of sympathetic nerves. Adiponectin plays anti-
inflammatory and anti-atherogenic roles and contributes 
to fat and glucose metabolism as well as energy balance in 
physiological conditions. Its role is not only a protective 
factor but also a risk factor for ESRD patients due to 
change in structure, proportion, and function of the 
kidney. In ESRD, circulatory adiponectin level increases 
for several reasons such as declined glomerular filtration 
and renal excretion of adiponectin, receptors resistance to 
adiponectin in uremic inflammation and decrease in these 
receptors, and metabolic disturbances. In ESRD, retention 
of water and salt and over activity of renin-angiotensin-
aldosterone system occurs that may lead to increase levels 
of circulatory adiponectin in the patients (14). Increased 
insulin resistance causes an increase in adiponectin in 
ESRD patients. In inflammatory conditions, rapid and 
dramatic weight loss changes regulation of inflammation 
factors and adiponectin. It was demonstrated that 
weight loss is associated with significant decrease in 
proteinuria (15). A large proportion of the world’s 
population are suffering from overweight and obesity 
(16). With increased urban population and income, the 
diets containing high amounts of sugar, fats, and animal 
products have replaced traditional diets that contain 
highly fibrous complex carbohydrates. Currently, high-
calorie foods and sedentary lifestyle are associated with 
obesity among children and adolescents (5).
Therefore, any modality taken to reduce obesity 
prevalence should not only aim to prevent obesity in the 
community (primary prevention) but also help to prevent 
further weight gain in obese and overweight people before 
development of complications due to obesity (secondary 
prevention). It seems that raising people’s knowledge 
and attitude toward selecting healthy foods is a strategy 
required to improve their diets. Besides that, strategies to 
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increase physical activity are considered a key part of any 
approach to prevent obesity. 
Conclusion
To deliver efficient health care services to prevent chronic 
diseases, pharmacotherapy is not sufficient and instead 
stable behaviors of healthy lifestyle should be promoted 
through long-term implementation (17). 
Authors’ contribution 
LM and SB searched and gathered the related articles. LM 
prepared the draft. SB edited the final manuscript. All 
authors read and signed the final paper.
Conflicts of interest 
The authors declare no conflicts of interest. 
Ethical considerations 
Ethical issues (including plagiarism, data fabrication, 





1. Obesity and overweight. WHO wensite. http://www.who.
int/mediacentre/factsheets/fs311/en/. Updated June 2016.
2. US Department of Health and Human Services (USDHHS). 
The Surgeon General’s Call to Action to Prevent and 
Decrease Overweight and Obesity. Rockville, MD: Public 
Health Service, Office of the Surgeon General; 2001.
3. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association 
between obesity and kidney disease: a systematic review 
and metaanalysis. Kidney Int. 2008;73:19–33.
4. Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity 
and its bioclinical correlates in the progression of chronic 
kidney disease. Adv Chronic Kidney Dis. 2006;13:352–364.
5. Stengel B, Tarver–Carr ME, Powe NR, Eberhardt MS, 
Brancati FL. Lifestyle factors, obesity and the risk of chronic 
kidney disease. Epidemiology. 2003;14:479-87.
6. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler 
J, Klag MJ. Risk of end-stage renal disease in diabetes 
mellitus: a prospective cohort study of men screened for 
MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 
1997;278:2069-74.
7. Hall JE, Brands MW, Henegar JR, Shek EW. Abnormal 
kidney function as a cause and a consequence of obesity 
hypertension. Clin Exp Pharmacol Physiol.1998;25:58-64.
8. Sarathy H, Henriquez G, Abramowitz MK, Kramer H, 
Rosas SE, Johns T, et al. Abdominal Obesity, Race and 
Chronic Kidney Disease in Young Adults: Results from 
NHANES 1999-2010. PLoS One. 2016;11:e0153588.
9. Malhotra R, Cavanaugh KL, Blot WJ, Ikizler TA, Lipworth 
L, Kabagambe EK. Dietary polyunsaturated fatty acids 
and incidence of end-stage renal disease in the Southern 
Community Cohort Study. BMC Nephrol. 2016;17:152.
10. Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, 
Altiparmak MR, et al. A population-based survey of 
Chronic REnal Disease In Turkey—the CREDIT study. 
Nephrol Dial Transplant. 2010;25:2745-53. doi: 10.1093/
ndt/gfq114.
11. Chang Y, Ryu S, Suh B, Yun K, Kim C, Cho S. Impact 
of BMI on the incidence of metabolic abnormalities in 
metabolically healthy men. Int J Obes (Lond). 2012;36:1187-
94. doi: 10.1038/ijo.2011.247.
12. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal 
disease. Am J Kidney Dis 2002;39:1–11.
13. Fantuzzi G. Adipose tissue, adipokines, and inflammation. 
J Allergy Clin Immunol. 2005;115:911-919.
14. Kato A, Odamaki M, Ishida J, Hishida A. Association of 
high-molecular-weight to total adiponectin ratio with pulse 
wave velocity in hemodialysis patients. Nephron Clin. 
Pract. 2008;109:18-24.
15. Morales E, Valero MA, León M, Hernández E, Praga M. 
Beneficial effects of weight loss in overweight patients 
with chronic proteinuric nephropathies. Am J Kidney Dis. 
2003;41:319-27.
16. Popkin BM. The nutrition transition and obesity in the 
developing world. J Nutr. 2001;131:871S-3S.
17. Swinburn BA, Caterson I, Seidell JC, James WP. Diet, 
nutrition and the prevention of excess weight gain and 
obesity. Public Health Nutr. 2004;7:123-46.
Copyright © 2017 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
